Invitae Expands Reproductive Health Offering with Launch of Comprehensive Genetic Carrier Screening
Invitae Expands Reproductive Health Offering with Launch of Comprehensive Genetic Carrier Screening -- New Testing Provides Affordable, Accessible Information for Parents-to-Be -- |
[25-June-2018] |
SAN FRANCISCO, June 25, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced the launch of the Invitae Carrier Screen, a comprehensive test designed to provide affordable, accessible information on genetic changes that pose a risk for parents of having a child with an inherited genetic disorder. Each year 7.8 million children worldwide are born with health problems caused at least in part by genetics1.
"By providing affordable, comprehensive, high-quality genetic information, Invitae carrier testing can help parents-to-be have the information they need to make appropriate health decisions when starting a family," said Robert Nussbaum, M.D., chief medical officer of Invitae. "Most often, people who are carriers of potentially serious alterations in a gene are unaware of their status and have no symptoms, known as 'silent carriers.' Carrier screening provides information about the risks of unknowingly passing along a genetic disorder from one or both parents to a child, which is why professional societies, such as the American College of Medical Genetics and Genomics and the American College of Obstetrics and Gynecology, recommend carrier screening for all people considering pregnancy." The Invitae Comprehensive Carrier Screen uses next-generation sequencing to identify changes in 287 genes linked to serious genetic disorders, including cystic fibrosis (CF), spinal muscular atrophy (SMA) and many other life-threatening disorders. The test identifies the vast majority (>99%) of disease-causing changes in most of the genes analyzed, compared to more limited approaches that test for only changes in genes most commonly seen in particular ethnic groups. Invitae's test is appropriate for people of all ethnicities who want a comprehensive assessment of their risk of having a child with a serious inherited genetic disorder. "We're building the industry's most comprehensive and affordable reproductive health offering, using our world-class expertise to increase access to genetic information when having a family," said Sean George, co-founder and chief executive officer of Invitae. "As we continue toward our goal to aggregate the world's genetic tests into a single service, the addition of carrier screening further strengthens our ability to provide genetic information to inform healthcare decisions through every stage of life." The panel includes screening for:
Beyond the 287-gene panel, Invitae also offers two additional pre-curated panels: a 46-gene test assessing a smaller set of common disorders and a targeted test consisting of the three genes associated with CF, SMA and Fragile X syndrome. These smaller panels can be supplemented with a customized set of additional genes from the larger 287-gene panel based on a person's specific needs. There are also an additional 13 genes not included in a pre-curated panel that can be added to any test. Turnaround times average 14 days, and testing is covered by most major insurers. Patients with insurance can elect to receive a personalized cost estimate based on their insurance coverage. For patients who do not go through insurance, any Invitae carrier screen, regardless of the number of genes, can be ordered for $250 with patient-pay. A reproductive partner discount is available for $100. Access to board-certified genetic counselors is available during the testing process for patients and clinicians as part of the service. The Invitae Carrier Screen replaces the existing GeneVu carrier screen previously ordered through Good Start Genetics, which was acquired by Invitae in 2017. The test extends the company's reproductive health testing services, which include preimplantation genetic screening (PGS), miscarriage analysis, pre-natal and neonatal testing. About Invitae Safe Harbor Statement Contact:
View original content with multimedia:http://www.prnewswire.com/news-releases/invitae-expands-reproductive-health-offering-with-launch-of-comprehensive-genetic-carrier-screening-300671332.html SOURCE Invitae Corporation | ||||
Company Codes: NYSE:NVTA |
© 2018 PR Newswire. All Rights Reserved.
#content-news .main-news{color:#737373;font-size:14px;line-height:inherit;text-align:inherit}